NKTR Stock Forecast: Nektar Therapeutics Price Predictions for 2026-2027

Last close, 20 Nov 2026
$30
−7.19% on the day

The median 12-month analyst price target for Nektar Therapeutics is $150. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.1B
Ticker Nerd rank
40/ 100
Median analyst target
$150
Analysts covering
15
Revenue$10.1M−9.3% y/y
Operating income−$41.8M
Net income−$40.6M
Free cash flow−$75.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.0%
1M
−23.0%
YTD
−28.6%
1Y
−45.2%
From 52W high
−69.9%
From 52W low
0.0%
$30
$100
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
40/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
74
Revisions
70
Issuance
48
Value
48
Growth
46
Momentum
42
Volatility
25
Accruals
7

Quality (74): The business earns solid, repeatable profits on what it owns.

Accruals (7): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NKTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Jan 26Apr 26Jul 26Oct 26NKTRHigh $192Median $150Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
11
Buy
4
Hold
0
Sell
$40
Low
$150
Median
$192
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
16 Nov 2026Canaccord GenuityMaintainsBuy$153 → $149
12 Oct 2026Leerink PartnersInitiatesOutperform$130
12 Oct 2026UBSInitiatesNeutral$53
9 Oct 2026BTIGReiteratesBuy$178
9 Oct 2026Raymond JamesInitiatesMarket Perform—
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$185
28 Sept 2026BTIGReiteratesBuy$178
25 Sept 2026BTIGReiteratesBuy$178
23 Sept 2026WedbushMaintainsNeutral$80 → $50
16 Sept 2026BTIGReiteratesBuy$178
9 Sept 2026BTIGReiteratesBuy$178
21 Aug 2026JP MorganReinstatesNeutral$65
22 July 2026Canaccord GenuityInitiatesBuy$153
11 May 2026WedbushMaintainsNeutral$95 → $80
8 May 2026Piper SandlerMaintainsOverweight$105 → $192
21 Apr 2026CitigroupMaintainsBuy—
21 Apr 2026WedbushMaintainsNeutral—
20 Apr 2026BTIGMaintainsBuy—
20 Apr 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026WedbushInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NKTR.

Market Radar

This page is one stock. Monday covers all of them.

NKTR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NKTR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Nektar Therapeutics returned −45.2% against +6.9% for the S&P 500, dividends included.

NKTR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26NKTRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NKTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
20.9×

Cheaper than 7% of US stocks

Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−37.9%

Higher than 25% of US stocks

Return on assets
−14.8%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nektar Therapeutics has a market value of $1.1B and an enterprise value of $627.7M.

  • Revenue in the twelve months to 30 June 2026: $54.6M. The latest quarter shrank 9.3% year on year.

  • Net income over the same four quarters: −$157.1M, a −287.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$6.70.

  • Free cash flow in the twelve months to 30 June 2026: −$234.0M.

  • Shares outstanding: 34.1M.

  • Nektar Therapeutics employs 63 people — $866K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NKTR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NKTRNektar Therapeutics$1.1B40
CTYCity Therapeutics, Inc.$999.3M1
INBXInhibrx Biosciences, Inc.$1.0B37
SGPSpyGlass Pharma, Inc.$1.0B1
ANROAlto Neuroscience, Inc.$986.1M57
OMEROmeros Corp.$983.7M81
SPTXSeaport Therapeutics, Inc.$957.2M13

Take a look at NKTR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NKTR

What is the NKTR stock price forecast for 2026-2027?

The median 12-month analyst price target for Nektar Therapeutics is $150, with estimates ranging from $40 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NKTR stock a buy right now?

Of the 15 analysts covering Nektar Therapeutics, 11 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 40 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NKTR?

As at 21 Nov 2026, Nektar Therapeutics ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (74 of 100).

Will NKTR stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts is $150, and Ticker Nerd's factor model ranks Nektar Therapeutics 40 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NKTR stock forecast for 2030?

No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $192 over the next 12 months.

How has NKTR stock performed over the past year?

Nektar Therapeutics returned -45.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nektar Therapeutics do?

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes.

Company

About Nektar Therapeutics.

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.

CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com